Delivery of nanogel formulations with antimicrobial peptides for the treatment of mycobacteriosis by Silva-Carvalho, Ricardo et al.
 83 
Delivery of Nanogel Formulations with Antimicrobial Peptides for the Treatment of 
Mycobacteriosis 
 
Ricardo Silva-Carvalho, Cecília Cristelo, João P. Silva, Olga Coutinho, António G. Castro, Jorge 
Pedrosa, Rui Appelberg, Miguel Gama 
CEB - Centre of Biological Engineering, Universidade do Minho, 4710-057 Braga, Portugal 
Group: FUNCARB Line: Health Biotechnology and Bioengineering 
 
Mycobacterium tuberculosis is the human pathogen that causes Tuberculosis (TB). In 2015, 10.4 million 
TB cases and 1.8 million deaths were reported, placing this disease alongside HIV/AIDS as the deadliest 
infectious diseases. Current treatments rely in the administration of a cocktail of four first-line antibiotics 
during 6 months and, in the worst case scenario, a long-lasting treatment (24 months) with second-line 
drugs. The overuse or misuse of antimicrobial agents decreases the success of treatments and increases 
emergence of Multi-drug resistant (MDR) strains. Therefore, the development of new strategies for TB 
therapy is urgently needed. In this scope, antimicrobial peptides (AMPs) arise as promising candidates 
for TB treatment since they present high spectrum of antimicrobial activity, high efficacy at low 
concentrations and low propensity for bacterial resistance. Nevertheless, the low capacity of AMPs to 
reach the infected site and the use of high concentrations to overcome this problem limits its clinical 
application - this can be circumvented using a drug delivery system [1].  
Recently, in a versatile, easy and reproducible manner, we developed a promising delivery system by 
grafting a hydrophobic molecule to Hyaluronic acid (HA). The amphiphilic conjugate self-assembles in 
aqueous environment, allowing the entrapment of bioactive molecules. We showed that LLKKK18-
loaded nanogels cause no BMMΦ death and no significant effect in terms of the number of apoptotic 
cells, regardless the treatment or whether the BMMΦ were or not infected with M. avium. Additionally, 
in vitro incubation of macrophages with LLKKK18-loaded nanogel reduced the intracellular levels of both 
M. avium and M. tuberculosis. Most importantly, the capacity of macrophages to internalize HA was 
confirmed by in vivo results obtained in a model of TB infection, where just a few drug administrations 
over a short period yielded a promising 1.2-log reduction of the microbial burden [2]. 
In future work we intend to optimize the nanogel formulations, by promoting the encapsulation of 
LLKKK18 or LLKKK18/antimicrobial drugs in the nanocarriers, and unravel the in vitro immunomodulatory 
and metabolic effect promoted by the formulations in different cell models of mice and human. Since 
thorough optimization of the formulations and process will be carried out, the in vivo efficacy of an 
aerosol delivery of the formulations to infected mice will be assessed using the inEXPOSE inhalation 
system during one month. The susceptibility of MDR mycobacteria strains, and the eventual resistance 
mechanisms, that arise upon long in vitro treatments with LLKKK18 will also be studied. 
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